Supplemental Data

Distribution, Metabolic Profiling and Identification, and Excretion of the Dual Reuptake Inhibitor [¹⁴C]-Nefopam in Rats

Jian Yu, Eric Solon, Helen Shen, Nishit B. Modi, Aravind Mittur

Xenobiotica

Supplemental Figure 1. Plasma radioactivity concentration versus time profile of nefopam and selected metabolites.

Supplemental Figure 2. LC-Radio-chromatograms of nefopam metabolites in the pooled urine of rats after oral administration of a single 20 mg/kg dose of [^{14}C]-nefopam.

Supplemental Figure 3. LC-Radio-chromatograms of nefopam metabolites in the pooled feces of rats after oral administration of a single 20 mg/kg dose of [^{14}C]-nefopam.

Supplemental Figure 4. XIC extracted ion chromatogram (XIC) and mass spectra of M22a and M22b at m/z 270 and the proposed fragmentation pathways.

Supplemental Figure 5. Extracted ion chromatogram (XIC) and mass spectra of M6a to M6c at m/z 446 and the proposed fragmentation pathways.

Supplemental Figure 6. Extracted ion chromatogram (XIC) and mass spectra of M7a to M7c at $m/z\ 464$ and the proposed fragmentation pathways.

Supplemental Figure 7. Extracted ion chromatogram (XIC) and mass spectra of M8a and M8b at m/z 462 and the proposed fragmentation pathways.

Supplemental Figure 8. Mass spectra of M9 at m/z 256 and the proposed fragmentation pathways.

Supplemental Figure 9. Mass spectra of M11 at m/z 270 and the proposed fragmentation pathways.

Supplemental Figure 10. Mass spectra of M14 at m/z 272 and the proposed fragmentation pathways.

Supplemental Figure 11. Mass spectra of M16 at m/z 286 and the proposed fragmentation pathways.